NNVC241115P5000
- 0.00
- 0.000.00%
Nanoviricides Newsroom
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy
Nanoviricides | 10-K: FY2024 Annual Report
NanoViricides Secures First Rights To TheraCour's Antiviral Developments, Eyes Phase II Trials For Lead Drug
Express News | NanoViricides: Obtained Right of First Refusal for All Antiviral Drug Developments From R&D Firm Theracour Pharma
NanoViricides Considers NV-387 for MPOX Treatment Under WHO Protocol Amid Global Outbreak
Express News | NanoViricides: Investigating Possibility of Using NV-387 for Treatment of Mpox Patients Under Who Meuri Protocol
NanoViricides Exploring Emergency Protocol to Evaluate NV-387 for MPOX | NYSE-A:NNVC
Express News | NanoViricides: Anil Diwan Visiting Professionals for Developing Phase II Clinical Trial Plan & Clinical Protocol for Phase II Clinical Trial of NV-387
Express News | NanoViricides: Plans on Exploring Effectiveness of NV-387 for Treatment of Severe Acute Respiratory Infections Caused by Viruses
NanoViricides' NV-387 Aims to Tackle RSV, COVID, and Flu in Upcoming Clinical Trials
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
The only manufacturer of smallpox vaccine has submitted clinical data and plans to expand the scope of vaccination.
Bavarian Nordic announced that it has submitted clinical data to the European Medicines Agency to seek an expansion of the indication for its Imvanex vaccine to adolescents aged 12-17. Yesterday, Sweden, the neighboring country of Denmark, reported the first confirmed case of monkeypox, which is also the first case confirmed outside the African continent since this epidemic outbreak.
NanoViricides Provides An Update On Its Clinical Program And Strategy In Its Letter To Shareholder, Says NV-387, An Antiviral Drug, Could Be As Revolutionary As Antibiotics
NanoViricides Reports Major Progress in Advancing Broad-spectrum Antiviral Drug NV-387 | NYSE-A:NNVC
NanoViricides' Lead Asset for Broad Spectrum Efficacy Wins Praise in Industry Reports | NYSE-A:NNVC
NanoViricides Shares Are Trading Higher After the Company Announced It Discussed Its Development Program for NV-387.
NanoViricides Discusses Lead Program and Next Steps | NYSE-A:NNVC
NanoViricides Hails Broad Potential of Lead Antiviral Drug as It Prepares to Begin First Phase II Trial | NYSE-A:NNVC
NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model | NYSE-A:NNVC
NanoViricides Hails the Potential of NV-387 in Combatting Bird Flu Virus H5N1 | NYSE-A:NNVC